FDA Clears Dupixent for Chronic Hives in Children as Young as 2

The U.S. Food and Drug Administration approved dupilumab (Dupixent) on April 22, 2026 for the treatment of chronic spontaneous urticaria in children aged 2 to 11 years, making it the first biologic medicine cleared in the U.S. for this age group with the condition. The approval covers children who remain symptomatic despite H1 antihistamine therapy. Sanofi and Regeneron, which co-develop Dupixent, reported that more than 14,000 children in this U.S. age range have CSU that is uncontrolled on antihistamines alone. Prior to this decision, no biologic option existed for children under 12 with the condition.

What Chronic Spontaneous Urticaria Actually Is, and Why Antihistamines Alone Fall Short

Chronic spontaneous urticaria is not a simple allergic response. It is an IgE-mediated or autoimmune-driven condition in which mast cells and basophils in the skin activate without an identifiable external trigger, releasing histamine and other inflammatory mediators that produce unpredictable wheals and intense itch. The "chronic" designation requires that episodes persist for at least six weeks with no identifiable cause.

In children, the condition carries significant burden beyond the skin. Disrupted sleep, school absences, and the psychological toll of visible, unpredictable flares compound the physical symptoms. H1 antihistamines are the first-line intervention, but a meaningful subset of pediatric patients does not achieve adequate control even at higher doses. Until April 22, that group had no FDA-cleared escalation option below age 12.

The gap between antihistamine response and full disease control traces back to the biology of CSU. Research in recent years has identified a significant type 2 inflammatory component in the condition, meaning the activation of mast cells and basophils is not purely histamine-mediated. Cytokines in the IL-4 and IL-13 family contribute to the sensitization and activation loop that sustains chronic urticaria, which is the same pathway targeted by dupilumab in atopic dermatitis. For more on how type 2 inflammatory pathways drive skin disease, see SkinCareful's coverage of the amlitelimab Phase 3 atopic dermatitis data.

How Does Dupilumab Treat Chronic Hives When Antihistamines Have Failed?

Dupilumab is a fully human monoclonal antibody that blocks the shared receptor subunit used by both IL-4 and IL-13 to signal, preventing both cytokines from driving downstream inflammation. This targets the type 2 pathway upstream of histamine release rather than blocking histamine receptors after mast cell degranulation, which is the mechanism of antihistamines.

In the LIBERTY-CUPID program, Studies A and C, which were replicate double-blind, placebo-controlled trials in patients aged 6 and older who had not previously received anti-IgE therapy, measured itch severity on the ISS7 scale and total disease activity on the UAS7 scale at week 24. Both studies demonstrated statistically significant improvements with dupilumab compared to placebo across these endpoints. The CUPIDKids Phase 3 trial specifically enrolled children aged 2 to 11 to assess pharmacokinetics and safety in the youngest patients; efficacy for this youngest cohort was extrapolated from the Studies A and C data given the shared underlying biology.

The safety profile in the 2-to-11 age group was consistent with dupilumab's known record across dermatological uses. Injection site reactions were the most frequently reported adverse event occurring more often in the dupilumab arm than placebo, at a rate of 2% or greater. No new adverse reactions were identified in children younger than 6.

The April 22 approval is the fifth indication for dupilumab covering children under 12 involving type 2 inflammation: atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and now CSU. The breadth of this list reflects the underlying biology rather than individual drug expansion: type 2 cytokine signaling is a common driver across conditions that look clinically distinct. This mechanism is also central to understanding why UV-driven skin inflammation and immune-mediated skin disease share overlapping inflammatory pathways.

When and How Will This Treatment Be Available for Young Children?

The approval is effective immediately as of April 22, 2026, and Sanofi and Regeneron have indicated that Dupixent will be available through existing specialty pharmacy channels. Prescriptions for this newly approved pediatric age group follow weight-based dosing: children weighing 5 to 15 kilograms receive 200 mg every four weeks; those weighing 15 to 30 kilograms receive 300 mg every four weeks. Neither group requires a loading dose, which differs from the dosing schedule for older patients who weigh 30 kilograms or more.

For children aged 6 to 17 in higher weight bands, the existing adolescent dosing schedule applies, including an initial loading dose.

International regulatory filings are expected to follow the U.S. decision. The European Medicines Agency and Health Canada reviews of this age expansion have not yet reported outcomes as of the date of this publication. According to the Regeneron investor press release issued April 22, 2026, the companies intend to pursue global approvals for this pediatric population, following the same regulatory pathway used for prior pediatric expansions of the drug. A Sanofi press release also details the full LIBERTY-CUPID clinical program supporting the approval.